Suppression by flavonoids of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells:

M Mutoh1, M Takahashi, K Fukuda

  • 1Cancer Prevention Division, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan.

Insights

Quercetin effectively suppresses cyclooxygenase-2 (COX-2) gene transcription in colon cancer cells. Structural features of flavonoids, like hydroxyl groups, are key for this suppressive activity, guiding the development of new cancer therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Cyclooxygenase-2 (COX-2) is implicated in cancer development.
  • Understanding COX-2 gene regulation is crucial for cancer therapy.

Purpose of the Study:

  • To investigate the suppressive effects of various flavonoids on COX-2 gene transcription.
  • To identify structural features of flavonoids responsible for COX-2 inhibition.

Main Methods:

  • Reporter gene assay in human colon cancer DLD-1 cells.
  • Structure-activity relationship analysis of twelve different flavonoids.
  • Chemical modification (bromination) to assess hydroxyl group importance.

Main Results:

  • Quercetin demonstrated the highest potency in suppressing COX-2 transcription (IC50 = 10.5 microM).
  • Catechin and epicatechin exhibited weak activity (IC50 = 415.3 microM).
  • Flavonoid structure, including hydroxyl groups on the B ring, an oxo group at C4, and low electron density on the A ring's hydroxyl group, significantly impacts COX-2 suppression.

Conclusions:

  • Flavonoid structure dictates their efficacy in suppressing COX-2 transcription.
  • Specific structural modifications, like bromination, can enhance suppressive potency.
  • Findings provide a foundation for designing novel COX-2 transcriptional suppressors for cancer treatment.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...